This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: The Board of Regents of the University of Nebraska. Active years: 2007.
Company Filing History:
Years Active: 2007
Title: The Innovations of Nicholas Nikolaides
Introduction
Nicholas Nikolaides is an accomplished inventor based in Mason, OH (US). He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of alpha-2 mediated disorders. His innovative work has led to the development of a unique compound that holds promise for addressing ocular hypertension.
Latest Patents
Nicholas Nikolaides holds a patent for the compound 6-[(4,5-Dihydro-1H-imidazol-2-yl)amino]-7-methyl-1H-benzimidazole-4-carbonitrile and its preferred salt, which is 6-[(4,5-Dihydro-1H-imidazol-2-yl)amino-]-7-methyl-1H-benzimidazole-4-carbonitrile substantially free of 2,3,7-triamino-4,6-dimethyl-1,9-phenazinedicarbonitrile. This compound, along with its anhydrous monoacetate salt, is particularly useful in treating conditions related to ocular hypertension. He has been granted 1 patent for this innovative work.
Career Highlights
Nicholas Nikolaides is affiliated with the University of Nebraska, where he continues to engage in research and development. His work is characterized by a commitment to advancing medical treatments through innovative chemical compounds. His contributions have been recognized within the academic and medical communities.
Collaborations
Nicholas has collaborated with notable colleagues, including Jared Lynn Randall and Richard Alan Gibbs. These partnerships have fostered a collaborative environment that enhances the research and development process.
Conclusion
Nicholas Nikolaides exemplifies the spirit of innovation in the pharmaceutical industry. His work not only contributes to scientific knowledge but also has the potential to improve patient outcomes in the treatment of ocular hypertension.